PF-00299804
Modify Date: 2024-01-09 20:48:08
PF-00299804 structure
|
Common Name | PF-00299804 | ||
|---|---|---|---|---|
| CAS Number | 1042385-75-0 | Molecular Weight | 487.95 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H27ClFN5O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PF-00299804Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC)[1]. |
| Name | (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide,hydrate |
|---|---|
| Synonym | More Synonyms |
| Description | Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC)[1]. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C24H27ClFN5O3 |
|---|---|
| Molecular Weight | 487.95 |
| Exact Mass | 487.178650 |
| PSA | 92.10000 |
| LogP | 5.75120 |
| Hazard Codes | Xi |
|---|
| (2E)-N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl}-4-(1-piperidinyl)-2-butenamide hydrate (1:1) |
| Dacomitinib [USAN:INN] |
| 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-, hydrate (1:1) |
| (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide, hydrate (1:1) |
| UNII-5092U85G58 |
| 2-Butenamide,N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-,hydrate (1:1),(2E) |
| Dacomitinib |
| dacomitinib hydrate |
| Dacomitinib hydrate (JAN) |
| (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}-4-(piperidin-1-yl)but-2-enamide monohydrate |
| Dacomitinib monohydrate |
| (2E)-N-(4-(3-Chloro-4-fluorophenyl)amino)7-methoxyquinazolin-6-yl)4-(piperidin-1-yl)but-2-enamide monohydrate |
| PF-00299804 |